← Inspire Medical Systems overview

Inspire Medical Systems vs Doximity: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Inspire Medical Systems Inc (INSP)

Q3 2026
▲4

Inspire's reimbursement fix and raised guidance drive the story

  • New CPT codes remove a key overhang The AMA approved new Category I billing codes for hypoglossal nerve stimulation, giving Inspire's procedures a permanent, clearer reimbursement path from 2028. This directly addresses the coding disruption that hurt sales, so it lifts confidence in future revenue and supports the stock.

    This is the biggest new regulatory catalyst and directly fixes the reimbursement problem that has weighed on INSP.

  • Q2 profit return and raised 2026 outlook Inspire swung to a small profit and beat earnings expectations, then raised full-year revenue and EPS guidance. Even though sales fell, the raised outlook signals management sees the worst of the reimbursement hit passing, which is why shares jumped double digits.

    The guidance raise and return to profit are the core fundamental drivers behind the period's positive move.

  • Project Horizon cuts costs to fund growth The restructuring aims to free up $30 million a year by streamlining operations and supply chain, money that can be reinvested in growth. It comes with $20–25 million in one-time charges, mostly in Q3, but the plan shows management is acting to stabilize the business.

    This explains the operational response to the reimbursement disruption and how the company plans to restore growth.

  • Board addition and peer-group strength Inspire added a seasoned medical device executive to its board, strengthening oversight. Separately, a peer review noted Inspire posted the highest full-year guidance raise among tracked device stocks, a sign its outlook stands out even as the stock remains down sharply this year.

    These are secondary but supportive signals of governance and relative performance that round out the picture.

August 2026
▲4

Inspire's reimbursement fix and raised guidance drive the story

  • New CPT codes remove a key overhang The AMA approved new Category I billing codes for hypoglossal nerve stimulation, giving Inspire's procedures a permanent, clearer reimbursement path from 2028. This directly addresses the coding disruption that hurt sales, so it lifts confidence in future revenue and supports the stock.

    This is the biggest new regulatory catalyst and directly fixes the reimbursement problem that has weighed on INSP.

  • Q2 profit return and raised 2026 outlook Inspire swung to a small profit and beat earnings expectations, then raised full-year revenue and EPS guidance. Even though sales fell, the raised outlook signals management sees the worst of the reimbursement hit passing, which is why shares jumped double digits.

    The guidance raise and return to profit are the core fundamental drivers behind the period's positive move.

  • Project Horizon cuts costs to fund growth The restructuring aims to free up $30 million a year by streamlining operations and supply chain, money that can be reinvested in growth. It comes with $20–25 million in one-time charges, mostly in Q3, but the plan shows management is acting to stabilize the business.

    This explains the operational response to the reimbursement disruption and how the company plans to restore growth.

  • Board addition and peer-group strength Inspire added a seasoned medical device executive to its board, strengthening oversight. Separately, a peer review noted Inspire posted the highest full-year guidance raise among tracked device stocks, a sign its outlook stands out even as the stock remains down sharply this year.

    These are secondary but supportive signals of governance and relative performance that round out the picture.

Latest
▲4

Inspire's reimbursement fix and raised guidance drive the story

  • New CPT codes remove a key overhang The AMA approved new Category I billing codes for hypoglossal nerve stimulation, giving Inspire's procedures a permanent, clearer reimbursement path from 2028. This directly addresses the coding disruption that hurt sales, so it lifts confidence in future revenue and supports the stock.

    This is the biggest new regulatory catalyst and directly fixes the reimbursement problem that has weighed on INSP.

  • Q2 profit return and raised 2026 outlook Inspire swung to a small profit and beat earnings expectations, then raised full-year revenue and EPS guidance. Even though sales fell, the raised outlook signals management sees the worst of the reimbursement hit passing, which is why shares jumped double digits.

    The guidance raise and return to profit are the core fundamental drivers behind the period's positive move.

  • Project Horizon cuts costs to fund growth The restructuring aims to free up $30 million a year by streamlining operations and supply chain, money that can be reinvested in growth. It comes with $20–25 million in one-time charges, mostly in Q3, but the plan shows management is acting to stabilize the business.

    This explains the operational response to the reimbursement disruption and how the company plans to restore growth.

  • Board addition and peer-group strength Inspire added a seasoned medical device executive to its board, strengthening oversight. Separately, a peer review noted Inspire posted the highest full-year guidance raise among tracked device stocks, a sign its outlook stands out even as the stock remains down sharply this year.

    These are secondary but supportive signals of governance and relative performance that round out the picture.

Doximity Inc (DOCS)

Q3 2026
▲3▼1

Doximity's AI Bet Pays Off With Blowout Quarter, But Margins Shrink

  • Blowout Q1 earnings and raised guidance Doximity reported fiscal Q1 revenue of $156.6 million, beating the $151.7 million consensus, and raised its full-year targets. The stock soared 66% in premarket trading. This directly boosts the share price because it shows the business is growing faster than expected and management is confident enough to raise guidance.

    This is the single biggest new event of the period and the main reason DOCS moved sharply higher.

  • AI investments show strong returns CEO Jeff Tangney said AI prompt volume grew over 25% quarter-on-quarter and AI Scribe users jumped tenfold year-over-year. An independent study found Doximity's AI assistant had the lowest clinical error rates. This supports the stock because it shows the company's heavy AI spending is producing real user growth and a competitive edge.

    It explains why investors are optimistic about the AI strategy despite near-term costs.

  • AI spending squeezes profit margins Adjusted gross margin fell 300 basis points to 88% due to higher AI compute costs, and management expects adjusted EBITDA margin to drop to 47% for the year. This pressures the stock because it means profits are shrinking even as revenue grows, and the company expects the spending to continue.

    It is the main counterweight to the positive AI news and a key reason the stock doesn't just go straight up.

  • AI Search and clinical AI adoption accelerate Doximity's AI Search business onboarded its first cohort across more than two dozen programs, and quarterly active workflow prescribers rose over 30% year-over-year, with 165 signed health-system AI clients. This lifts the stock because it shows new AI products are gaining traction and opening a multibillion-dollar market beyond the core physician network.

    It provides concrete evidence that the AI pivot is translating into new customers and revenue streams.

July 2026
▲3▼1

Doximity's AI Bet Pays Off With Blowout Quarter, But Margins Shrink

  • Blowout Q1 earnings and raised guidance Doximity reported fiscal Q1 revenue of $156.6 million, beating the $151.7 million consensus, and raised its full-year targets. The stock soared 66% in premarket trading. This directly boosts the share price because it shows the business is growing faster than expected and management is confident enough to raise guidance.

    This is the single biggest new event of the period and the main reason DOCS moved sharply higher.

  • AI investments show strong returns CEO Jeff Tangney said AI prompt volume grew over 25% quarter-on-quarter and AI Scribe users jumped tenfold year-over-year. An independent study found Doximity's AI assistant had the lowest clinical error rates. This supports the stock because it shows the company's heavy AI spending is producing real user growth and a competitive edge.

    It explains why investors are optimistic about the AI strategy despite near-term costs.

  • AI spending squeezes profit margins Adjusted gross margin fell 300 basis points to 88% due to higher AI compute costs, and management expects adjusted EBITDA margin to drop to 47% for the year. This pressures the stock because it means profits are shrinking even as revenue grows, and the company expects the spending to continue.

    It is the main counterweight to the positive AI news and a key reason the stock doesn't just go straight up.

  • AI Search and clinical AI adoption accelerate Doximity's AI Search business onboarded its first cohort across more than two dozen programs, and quarterly active workflow prescribers rose over 30% year-over-year, with 165 signed health-system AI clients. This lifts the stock because it shows new AI products are gaining traction and opening a multibillion-dollar market beyond the core physician network.

    It provides concrete evidence that the AI pivot is translating into new customers and revenue streams.

Latest
▲3▼1

Doximity's AI Bet Pays Off With Blowout Quarter, But Margins Shrink

  • Blowout Q1 earnings and raised guidance Doximity reported fiscal Q1 revenue of $156.6 million, beating the $151.7 million consensus, and raised its full-year targets. The stock soared 66% in premarket trading. This directly boosts the share price because it shows the business is growing faster than expected and management is confident enough to raise guidance.

    This is the single biggest new event of the period and the main reason DOCS moved sharply higher.

  • AI investments show strong returns CEO Jeff Tangney said AI prompt volume grew over 25% quarter-on-quarter and AI Scribe users jumped tenfold year-over-year. An independent study found Doximity's AI assistant had the lowest clinical error rates. This supports the stock because it shows the company's heavy AI spending is producing real user growth and a competitive edge.

    It explains why investors are optimistic about the AI strategy despite near-term costs.

  • AI spending squeezes profit margins Adjusted gross margin fell 300 basis points to 88% due to higher AI compute costs, and management expects adjusted EBITDA margin to drop to 47% for the year. This pressures the stock because it means profits are shrinking even as revenue grows, and the company expects the spending to continue.

    It is the main counterweight to the positive AI news and a key reason the stock doesn't just go straight up.

  • AI Search and clinical AI adoption accelerate Doximity's AI Search business onboarded its first cohort across more than two dozen programs, and quarterly active workflow prescribers rose over 30% year-over-year, with 165 signed health-system AI clients. This lifts the stock because it shows new AI products are gaining traction and opening a multibillion-dollar market beyond the core physician network.

    It provides concrete evidence that the AI pivot is translating into new customers and revenue streams.